New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties.

[1]  J. Boucher,et al.  Inhibitory effects and spectral interactions of isomeric methoxyindazoles on recombinant nitric oxide synthases. , 2003, Nitric oxide : biology and chemistry.

[2]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[3]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[4]  Ana Martínez,et al.  Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? , 2002 .

[5]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[6]  A. Kashuba,et al.  Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline. , 2002, Current opinion in investigational drugs.

[7]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[8]  K D Watenpaugh,et al.  Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. , 1998, Journal of medicinal chemistry.

[9]  J. Macdonald.  CHAPTER 23. NITRIC OXIDE SYNTHASE INHIBITORS , 1996 .

[10]  J. Kerwin,et al.  The arginine‐nitric oxide pathway: A target for new drugs , 1994, Medicinal research reviews.

[11]  J. Powers,et al.  Mechanism-based isocoumarin inhibitors for trypsin-like serine proteases involved in blood coagulation , 1987 .

[12]  Stewart A. Brown,et al.  The natural coumarins : occurrence, chemistry, and biochemistry , 1982 .